Defining System Requirements for Simplified Blood Culture to Enable Widespread Use in Resource-Limited Settings by Dailey, Peter et al.
Dailey, Peter; Osborn, Jennifer; Ashley, Elizabeth; Baron, Ellen;
Dance, David; Fusco, Daniela; Fanello, Caterina; Manabe, Yukari;
Mokomane, Margaret; Newton, Paul; Tessema, Belay; Isaacs, Chris;
Dittrich, Sabine (2019) Defining System Requirements for Simplified
Blood Culture to Enable Widespread Use in Resource-Limited Set-
tings. Diagnostics, 9 (1). p. 10. DOI: https://doi.org/10.3390/diagnostics9010010
Downloaded from: http://researchonline.lshtm.ac.uk/4650896/
DOI: 10.3390/diagnostics9010010
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
diagnostics
Article
Defining System Requirements for Simplified Blood
Culture to Enable Widespread Use in
Resource-Limited Settings
Peter J. Dailey 1,2,† , Jennifer Osborn 1,†, Elizabeth A. Ashley 3,4 , Ellen Jo Baron 5,
David A. B. Dance 3,6,7 , Daniela Fusco 8,9, Caterina Fanello 3,10, Yukari C. Manabe 11,
Margaret Mokomane 12, Paul N. Newton 3,6,7, Belay Tessema 13 , Chris Isaacs 1 and
Sabine Dittrich 1,*
1 Foundation for Innovative New Diagnostics (FIND), Malaria and Fever Program, Chemine des Mines 9,
Geneva 1202, Switzerland; Peter.Dailey@finddx.org (P.J.D.); jennifer.osborn@finddx.org (J.O.);
chris.isaacs@connected-dx.com (C.I.)
2 Division of Infectious Disease & Vaccinology, School of Public Health, University of California,
Berkeley 94720, CA, USA
3 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford,
Oxford OX1 3SY, UK; liz@tropmedres.ac (E.A.A.); david.d@tropmedres.ac (D.A.B.D.);
Caterina@tropmedres.ac (C.F.); Paul.Newton@tropmedres.ac (P.N.N.)
4 Myanmar Oxford Clinical Research Unit, Yangon, Myanmar
5 Department of Pathology, Stanford University, Palo Alto 94304, CA, USA; ejbaron@stanford.edu
6 Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital,
Vientiane, Lao PDR
7 Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
London WC1E 7HT, UK
8 Pole of Clinical Research, French Institute of Health and Medical Research, Paris 75013, France;
fusco@bnitm.de
9 Department of Epidemiology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine,
Hamburg 20359, Germany
10 Kinshasa Mahidol Oxford Research Unit, University of Oxford and Kinshasa School of Public Health,
Kinshasa, The Democratic Republic of Congo
11 Division of Infectious Diseases, Department of Medicine, School of Medicine,
Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; ymanabe@jhmi.edu
12 National Health Laboratory, Gaborone, Botswana; bafanamargaret@gmail.com
13 Department of Medical Microbiology, College of Medicine and Health Sciences, University of Gondar,
Gondar, Ethiopia; bt1488@yahoo.com
* Correspondence: sabine.dittrich@finddx.org
† These authors contributed equally to this work.
Received: 15 October 2018; Accepted: 26 December 2018; Published: 11 January 2019


Abstract: Bacterial blood stream infections (BSI) are a common cause of mortality and morbidity
globally. As the causative agents and the resulting treatment decisions vary, near-patient testing
and surveillance tools are necessary to monitor bacterial causes and resistance to antimicrobial
agents. The gold standard to identify BSIs is blood culture (BC), a methodology not widely available
in resource-limited settings. The aim of the study was to map out a target product profile of
a simplified BC system (SBCS) to inform product development efforts. To identify the desired
characteristics of a SBCS, we enlisted a small group of specialists working in Africa and Asia.
Questions were used to understand challenges and how these constraints inform system requirements.
The specialists were infectious disease physicians, public health/clinical microbiologists, clinical
researchers, and technology experts with different geographical backgrounds. All suggested that BC
should ideally be available at the district hospital level. Many of the same operational challenges,
such as limited availability of culture bottles, electricity and internet connectivity, profuse dust,
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the lack of ambient temperature control, and human capacity constraints were identified across the
different regions. BCs, although the accepted gold standard for diagnosis of BSIs, are not widely
available outside of reference/research centers in Africa and Asia. To extend the reach of this
important tool, it is crucial to engage product developers and academic research partners to develop
accessible alternatives.
Keywords: blood culture; hemoculture; target product profile; low- and middle-income countries;
LMICs; resource limited; microbiology; AMR; sepsis
1. Introduction
The World Health Assembly and World Health Organization (WHO) have recognized sepsis as a
global public health priority [1]. Sepsis is a major worldwide health and economic burden [2] and it
has been estimated that there are 31 million cases of sepsis per year worldwide with 6 million patient
deaths [1]. Sepsis is also a frequent cause of the death of neonates and children less than 5 years of
age [3]. Blood culture is an essential laboratory procedure that can influence the treatment of patients
with sepsis [4]. Results of blood cultures (BCs) also play a critical role in informing regional empiric
therapy guidelines and the tracking of antimicrobial susceptibility trends and patterns [2]. BC was
pioneered in the early and mid-20th century [5] with minor later improvements in the method due
to the automated detection of positive BCs [6]. In recent years, new technologies were developed
to enable more rapid identification of pathogens and detection of resistance markers from positive
BCs [7]. However, they have not replaced the basic elements of conventional BC or the testing that
is required following the detection of a positive sample, like identification (ID) of the organism and
antimicrobial susceptibility testing (AST). To this day, BC remains the gold standard method to detect
bloodstream infections and for tracking of antimicrobial resistance (AMR), despite being labor intensive
and complex [4]. Unfortunately, clinical microbiology laboratory capacity is limited and underutilized
in many low- and middle-income countries (LMIC) [8–12], a shortcoming increasingly recognized
in the context of AMR interventions and surveillance. BCs are challenging to implement due to the
length of time to return results to patients and the perceived lack of impact on treatment. Further,
there is a necessity for sophisticated laboratory facilities and high costs due to the need for a multitude
of different reagents. Further, highly-trained staff is also required at all steps, requiring sophisticated
sustainable capacity implementation. Uptake by clinicians may also be poor due to the length of
time from sample collection to result and inadequate liaison between the laboratory and wards and
the often-perceived lack of quality and utility of the results from the laboratory [8,10,13]. Recent
international initiatives have been directed at improving laboratory capabilities in low-resource areas
with a specific focus on general microbiology facilities [14,15]. Along with the extensive capacity
improvement activities that are ongoing to support the global fight against rising AMR, there is a
need to enrich the diagnostic landscape with new tools appropriate for use in these regions [16].
The purpose of this work was to draft a target product profile (TPP) to inform product developers
of the requirements of a simplified BC system applicable in resource-limited settings. TPPs inform
academic and commercial product developers of key characteristics and the performance specifications
of a test system that are required to meet the end users’ needs for a defined use case [17–19]. Beyond
informing technology innovators, the development of TPPs helps to raise the profile and promote the
need for a certain type of diagnostic tool. TPPs include optimal and minimal definitions for each test
performance characteristic. Optimal characteristics describe the ideal, but often technically challenging,
specifications. The minimal requirements define the user needs essential to meet the intended use
of the test system to be a useful diagnostic tool. Ideally, products should be designed to achieve
as many of the optimal characteristics as feasible, while still satisfying the minimal criteria for all
defined features.
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We sought to define product features that address challenges specific to resource-limited settings
and encourage product development efforts for simplified BC systems that are suitable for these
localities and could be used as near-patient tests hospitals outside of the big reference centers.
2. Materials and Methods
2.1. Specialist Interviews
A series of eight interviews (nine individuals at eight separate locations) were conducted to
explore the needs and barriers for performing BCs in resource limited settings (authors: E.A.A., E.J.B.,
D.A.B.D., D.F., Y.C.M., M.M., P.N.N., and B.T.). Stakeholders were a convenient sample of experts with
relevant and regional expertise. Stakeholders included infectious disease physicians (n = 3), public
health/clinical microbiologists (n = 4), a clinical researcher (n = 1), and a technology expert (n = 1). They
were based at hospitals in Asia (n = 3) and Africa (n = 5), or in the USA (and multiple low-resource
areas = 1). Stakeholders were selected to represent laboratory settings ranging from level 4 to level
2 health facilities [20], with or without ongoing BC testing capacity. Interviewees were selected to
represent experiences from different regions and levels of capacity to establish needs and gaps across
a spectrum of laboratories, settings and cultures. All were affiliated with public sector sites and/or
academic institutions. Structured phone interviews (~60–120 min) were conducted using an interview
guide that included an overview of the workflow of standard BCs to guide the discussion. Specific
questions were developed by the FIND-team (authors: P.J.D., J.O., and S.D.), which addressed each BC
process step from sample collection to results to understand current procedures, needs, and challenges
(Supplementary Materials). The same guidance documents were used for all calls and the same
interviewers were in the calls to avoid bias. The aim was to summarizes a broad range of topics that
could which were then used as the basis of a more simplified blood culture system, assuming that the
current system was suboptimal. Responses were summarized in an Excel database and, after obtaining
oral or consent, all interviews were voice recorded for later verification. Commonalities between
respondents were summarized and key findings were distilled from these records.
2.2. Target Product Profile Development Process
A list of the essential product characteristics for a simplified BC system was compiled based on
FIND internal templates (https://www.finddx.org/target-product-profiles/). These key characteristics
and the responses from the interviews were used to develop an initial TPP draft. Published standards
and guidelines for conventional BC system requirements were also incorporated into some of the
minimal and optimal characteristics, where applicable [20,21]. To obtain the TPP presented here,
an adapted Delphi-like process [18] was used. In brief, the first draft of the TPP was developed from
the interview responses and shared with all specialists, then comments and corrections were collected
and incorporated for the next version. The second draft of the TPP was shared back and agreement
was thought for more controversial characteristics in individual communication. Previous published
definitions [22] for the health system levels were used in the TPP and “near-patient testing” in this
case does include laboratory testing, albeit outside of big reference centers.
3. Results
3.1. Current Use of BCs in Low Resource Settings
Only half (4/8, 50%) of the interviewees worked at sites currently operating a BC system (Table 1).
Sites were donor-supported and not typical of most hospitals in their countries. The remaining
stakeholders (n = 4) had in-depth knowledge of settings or facilities representative of their region,
though their current sites were not actively performing BC. A multitude of challenges were described
by all (Table 2) and these challenges were then used to inform the TPP characteristics outlined below.
Of the four sites performing BCs, only one was open 24/7, and this was a reference level health facility.
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Three of four sites performed Gram stains on positive BCs. Reliable patient identification was raised as
a point of concern in multiple settings as many patients do not know their birthdate, names are often
very similar, and many countries do not have national identification numbers or effective hospital
patient numbering systems. All four BC sites were collecting blood from patients by syringe and
needle following skin decontamination with alcohol and/or iodine. Only (2/4, 50%) had access to
“butterfly” needles for difficult and pediatric draws. Their use was impeded by the additional cost.
Failure to collect the recommended blood volume was commonplace (7/8, 88%), despite standard
guidelines for BC in adults recommending drawing 10 mL of blood in two bottles (total 20 mL), two to
three times [21]. In many settings described in the interviews, this is not common practice and usually
only one bottle is collected. In some locations, particularly in Southeast Asia interviewees described a
general reluctance to draw large volumes of blood. The information collected in the interviews was
used to develop this preliminary TPP (Table 3). Describing the challenges and translating the current
shortcomings into technical requirements in the TPP characteristics aims to inform researchers and
provide the basis for transformative innovation.
3.2. Target Product Profile
3.2.1. Scope of the test
Stakeholders emphasized the importance of BCs in providing data for pathogen and AMR
surveillance and in improving local empiric treatment guidelines. Based on the stakeholders’ input,
the target population was defined as: All patients presenting with fever, including neonates and
immunocompromised individuals. The acceptable target user was defined as a moderately trained
technician, with 3–6 months of training. This was specified because several (3/8, 38%) respondents
noted that staff retention was a significant barrier. Stakeholders agreed that BC systems should be
available at level 2 facilities. For all but one site (Lao PDR) in which a long-term research project
supported BCs, patients were required to pay for BCs. The acceptable per test cost was determined to
be < $10 USD, with < $5 USD desired if BCs are predominantly used to inform patient care.
3.2.2. Test Performance
Interviewees agreed that a simplified system should include automated detection of a positive
culture and ideally be able to identify pathogens and perform AST. The diagnostic accuracy values
were estimated and set to > 95% sensitivity for detection of positive BC using standard blood culture
methodologies, for either a mono-microbial or a poly-microbial infection. The ability to distinguish
poly- from mono-microbial infection was considered an optimal requirement. TPP requirements for
interfering substances were specifically drafted to address conditions common to LMICs, such as the
frequent use of over the counter antibiotics [27] and malaria coinfection.
3.2.3. Test Procedure
All interviewees reported a preference for systems that would reduce staff errors and training
requirements and increase clinician trust in BC results. The TPP characteristics were informed by the
level of staff training and test complexity typical to level two facilities based on predefined criteria
for microscopy centers [19]. Blood sample collection was consistently reported to be a challenge
and stakeholders reported inadequate training and complex blood collection procedures resulting in
contamination rates as high as 15% (reported range: 5–10%), compared to 3–5% in the USA or Europe
and an international target of 2–3% [22,32]. To address cases where significant sample transport time or
delayed entry into an automated system may occur, incubation of culture bottles at 35 ◦C was preferred.
All sites reported inadequate or non-existent quality control of BC bottles or media. For sites that
prepared their own media, half reported minimal checks for sterility of the media preparation. In one
country, media is purchased by many laboratories from one centralized manufacturer, which does
extensive quality control on culture media.
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Table 1. Overview of blood culture (BC) methods in use at interviewed sites or representative countries. Only aerobic cultures were performed across all sites,
and bottles were incubated for seven days. Costs at interview sites ranged from a cost of $5–7 USD per test and up to $25 USD was reported in one case. All sites
currently performing BCs reported that nurses were the primary health providers collecting blood samples, though at some sites physicians (2/4, 50%) and lab
technicians (1/4, 25%) also collecting samples. The expertise of the interviewees from the different countries were infectious disease physicians (Lao PDR, Myanmar,
Cambodia), public health/clinical microbiologist (Ethiopia, Botswana).
City, County Level [22] CurrentSystem
Media
Preparation Delayed Entry QC of Reagents Reporting Protocol Identification AST
Vientiane, Lao
PDR 3–4
Manual,
daily check
for turbidity;
blood
Local
Sample transport from remote locations,
try to receive within 24 hours of
collection; transport at RT in a
double-skinned insulated metal box
QC for agar made
in-house
Gram stain, some rapid dx tests
performed and the preliminary result is
communicated verbally to clinicians
ASAP and updated on a daily basis until
there is a written a final report
API® (bioMerieux) Disk diffusion
Multiple,
Cambodia 3
Manual,
daily check
for turbidity
Local Ideally immediate; transport at RT Central QC for mediaat manufacturer
Lab to call ward to inform doctor of
result Manual biochemical Disk diffusion
Gondar,
Ethiopia 3–4
Manual,
daily check
for turbidity
Local Ideally immediate, can be small delays;transport at RT
QC on media for
sterility
Preliminary reports: growth
(turbidity)—report Gram stain
preliminary report, and finally drug
susceptibility
Gram stain and then
biochemical tests for Gram
negative organism
Disk diffusion
Gaborone,
Botswana 4
Manual,
daily check
for turbidity
Procure Ideally immediate, though delays up to8 h; transport at RT QC on media
Positive results reported in Laboratory
Information Systems for some facilities;
but manual reports are collected by
hospital wards daily
Manual biochemical Disk diffusion
Multiple,
Myanmar 3–4
Majority are
manual Local
Overnight delays > 12 h are common;
transport at RT No Final report (~7 days)
Manual Biochemical (few
level 4 centers are
introducing Vitek2)
Disk diffusion (automated methods
available for selected patients at very
few Level 4 centers)
ASAP: As soon as possible; dx: Diagnosis; QC: Quality control; RT: Room temperature; AST: Antimicrobial susceptibility testing.
Table 2. Summary of challenges for performing BC in low-resource settings, based on responses from interviewed specialists in multiple countries. Responses were subjective
assessments by the interviewed and are not necessarily transferrable to all settings in the respective country. The following definitions for three colors were used: Green = no
challenge, yellow = some challenges, red = significant challenges, white = unsure/question not answered. The expertise of the interviewees from the different countries were
infectious disease physicians (Lao PDR, Myanmar, Cambodia), public health/clinical microbiologist (Ethiopia, Botswana, Guinea) and clinical researcher (DR Congo).
Environmental Challenges Implementation Challenges
Country Available at
level
Power Dust Lab Temperature
control
Humidity Connectivity Level of lab staff
training
Quality Control for
BC
Sample Collection
(Volume, training)
Specimen Tracking Result Reporting
Lao PDR 3–4
Cambodia 3
Ethiopia 3–4
Botswana 4
Guinea 4 *
Myanmar 3
DR Congo 3
Uganda 3–4
* Only urine culture capacity available at the capital. PDR: People’s Democratic Republic, DR: Democratic Republic.
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Table 3. Proposed target product profile for a simplified BC system based on stakeholder input and international guidelines.
Characteristic Minimal Optimal Additional References
SCOPE
Goal A simplified blood culture system suitable for resource limited settings to support patient management and surveillance activities
Target population Total population (including neonates and immunocompromised individuals) presenting with fever
Target level of health system Level 3 (Regional/Provincial Hospital) and above Appropriate for use in level 2 (District Hospital) [22]
Target user Moderately trained lab technicians (e.g., 1–2 year certificates) Lab technicians with limited training (e.g., 3–6 months, able tooperate an integrated test with minimal additional steps) [9]
Platform cost < US $20,000 < US $5000
Price of individual test (2 culture bottles) < US $10 per test < US $5 per test
TEST PERFORMANCE
System detection capabilities
- Culture positivity, Gram status;
- Antimicrobial susceptibility can be determined with
additional methodologies
Pathogen identification and antimicrobial susceptibility are
automated outputs of the system
Pathogen detection > 95% sensitivity for detection of positive BC for either monomicrobial or polymicrobial
Pathogen identification Identifies 90% of isolates to species level, 95% genus level Identifies 95% to species level, 99% to genus level
Standard BC and identification
by MALDI-TOF MS is the
reference [23,24].
Ability to determine the presence of mixed
BCs
Not able to determine monomicrobial from polymicrobial
infections
Able to determine monomicrobial from polymicrobial
infections
Interfering substances Able to provide an accurate result in the presence of malariainfection [25,26]
Able to provide an accurate result in the presence of malaria
infection and/or antibiotics [27]
TEST PROCEDURE
Ease of use/test complexity
The entire test procedure for system operation after sample
collection to result should require a maximum of 2 steps by the
user
The entire test procedure for system operation after sample
collection to result should require a maximum of 1 step by the
user and no additional steps required by user after the sample
has been placed into the instrument
[19]
Sample volume
- Test consumable (culture bottle) should support smaller
volumes (5 mL or less) for pediatric samples and low volume
draws;
- Separate culture bottles for pediatric samples are acceptable
The same test consumable (culture bottle) should support
smaller volumes (5 mL or less) for pediatric samples and low
volume draws
International and local guidelines
regarding blood volumes and
number of samples collected
should be followed
Delayed entry - Allows for room temperature storage of BC bottles post collection for <4 h prior to culture;- If sample transport takes longer than 2 h, incubation at 35 ◦C is preferred [22]
QC testing of BC bottles Same as standard BC [28]
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Table 3. Cont.
Characteristic Minimal Optimal Additional References
TEST RESULTS
Preliminary result Test reports positive or negative culture results Test reports culture positive and > 95% Gram status andmorphology information
Final result Provides pathogen identification
Provides pathogens identification with resistance categories of
interest (MRSA vs. MSSA, ESBL producing Enterobacteriaceae)
and CRE
[29]
Antimicrobial susceptibility testing Antimicrobial susceptibility determination requires separatemethodologies
Antimicrobial susceptibility is included as an automated
output of the test result and therapy recommendations based
on local treatment guidelines
Data interpretation and output
- Alert for preliminary and final report;
- Capable of paper-based and electronic results to not only
laboratory, but physician and ward of patient
Minimal requirements in addition to therapy recommendations
based on local treatment guidelines
CONSUMABLES
Sample collection components None provided All components required for sample collection are included inthe kit
BC bottles Only compatible with BC media bottles from the testmanufacturer
Compatible with local manufacture of BC media bottles with a
specified media formulation
Sample tracking/Patient identification Compatible with 2D barcodes and labels Stakeholder interviews
Storage conditions of BC bottles 6 months at + 5
◦C to 35 ◦C, 70% humidity, including transport
stress (48 h at 50 ◦C); no cold chain required
12 months at + 5 ◦C to + 40 ◦C at 90% humidity & transport
stress (72 h at 50 ◦C); no cold chain required
High environmental
temperatures and high humidity
is often a problem in many
countries. High environmental
temperatures and high humidity
is often a problem in many
countries [30].
Shipping conditions of consumables & kit No cold chain required; tolerance of transport stress for aminimum of 48 h at 5 ◦C to + 40 ◦C
No cold chain required; tolerance of transport stress for a
minimum of 72 h at 5 ◦C to + 40 ◦C
Refrigerated transport is costly
and often cannot be guaranteed
during the entire transportation
process. Frequent delays in
transport are commonplace [30].
Waste disposal Consumables should be able to be disposed of as biohazardous waste as specified by WHO guidelines according to the safemanagement of waste from health-care activities or per country regulations [31]
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Table 3. Cont.
Characteristic Minimal Optimal Additional References
OPERATIONAL CHARACTERISTICS
Biosafety
Same as standard BC in a closed system;
Biosafety alert is provided when a pathogen identified is on a
predefined biosafety list
- No need for a biosafety cabinet; basic safety procedures need
to be followed (standard PPE);
- Alarms present for organisms that pose a biosafety risk for
laboratory acquired infections
Operating conditions
- Between + 10 ◦C to + 35 ◦C at 70% humidity and at a max
altitude of 2000 meters above mean sea level;
- Ability to function in a high dust environment, with manual
cleaning via standard lab consumable clean wipes or cleaning
tool provided with the instrument
- Between + 5 ◦C to + 40 ◦C at 90% humidity and at a max
altitude of 3000 meters above mean sea level;
- Ability to function in a high dust environment with minimal
manual cleaning required by user
High environmental
temperatures and high humidity
and dust are often an issue in
LMICs. High environmental
temperatures and high humidity
and dust are often an issue in
LMICs.
MALDI-TOF MS: Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; QC: Quality control; ESBL: Extended spectrum beta-lactamases; MSSA: Methicillin-sensitive
Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus; CRE: carbapenem-resistant Enterobacteriaceae; WHO: World Health Organization; PPE: Personal
protective equipment.
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3.2.4. Test Results
To inform the TPP characteristics related to test results, we discussed how BC results were reported
in each facility (Table 1). Results were not available in a timely fashion because the laboratory did not
often communicate preliminary results at six of eight sites (75%). As a minimum requirement, reporting
of preliminary results of a positive BC, ideally with Gram stain information, is required to inform
clinical decisions as quickly as possible. For the minimal requirements, results from antimicrobial
susceptibility testing by a separate method were acceptable. However, interviewees unanimously
expressed an interest in automated AST information from an integrated simplified BC system, which
was included as the desired characteristic. The addition of therapy recommendations based on
local treatment guidelines to accompany BC test results was mentioned as a useful addition to
facilitate treatment guidance for clinicians by 3/8 (38%) interviewees and was included as an optimal
requirement for data interpretation and output.
3.2.5. Consumables and Operational Characteristics
The optimal requirement calls for inclusion of sample collection supplies with the BC bottle
test kit to address this limitation. Media formulations can have significant impact on a technology’s
detection method, hence, the minimal requirement was restricted to compatibility of a designated
manufacturer’s BC bottle and the optimal case would allow for locally produced media formulations.
Several sites expressed an interest in biosafety alerts for hazardous agents including Burkholderia
pseudomallei, Brucella spp., and Bacillus anthracis.
3.2.6. Cultural Considerations Beyond the TPP
A recurring theme brought up by the specialists was that technology solutions alone will not
address all the challenges currently impeding the use of BCs in resource-limited settings. Even if a
timely result was provided to clinicians, stakeholders reported that a lack of trust in results often
leads clinicians to ignore laboratory results in their decision-making. Stakeholders suggested that
clinicians need education on the use of empiric therapy guidelines and BCs, since limited availability
of quality BC facilities can result in a lack of knowledge and training. There is a need to educate
clinicians to drive demand for BC from the clinician, not from the laboratory, and regularly enhanced
laboratory-ward/outpatient clinical liaison. Further, supply chain issues, stock-outs, and bureaucratic
challenges are barriers for diagnostic and therapeutic availability. Based on the small sample number,
it appeared that supply chain issues were more prevalent in Asia.
4. Discussion
Faster and more accurate diagnosis of bloodstream infections in low-resource areas is critical
for effective patient management, surveillance of AMR, and development of local empiric therapy
guidelines. For example, based on the interview feedback Guinea, a county of 12.4 million inhabitants,
does not have a microbiology facility capable of performing pathogen ID and AST, even at the
highest level of the health system. This results in a lack of data to inform treatment and public
health interventions [11]. In parallel to the work reported here, the BACTI-LRS consortium also
highlighted this need in a similar initiative, which explored requirements to implement bacteriology in
resource-limited setting LMICs [8].
The aim of the current report was to identify the challenges and gaps to performing BCs and
suggest how new innovations could address them in the form of a simplified BC system. Although
this is one solution to the problem, the general lack of laboratory capacity, supply chain constrains,
and human and infrastructure hurdles remain, and need to be addressed in parallel. Albeit anecdotal,
interviewees hinted at overall improved supply chains following the U.S. President’s Emergency Plan
for AIDS Relief (PEPFAR) initiative that also resulted in better microbiology supply access. This is
encouraging and demonstrates that barriers can be overcome if global health players unite around
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the same goals. In addition to the technical and capacity challenges reported by the interviewees,
our findings highlight the cultural issues and the need for continued education around the use, utility
and safety of BCs.
Although this report adds new knowledge on the technical needs, the work also has limitations
that might have introduced bias and might justify additional work and consensus building if this work
results in significant interest by product development partners. In brief, our interviews included only
a small number of stakeholders representing two continents who might have given a narrow view of
the situation. Further, the interview team assumed that current systems are suboptimal, potentially
further introducing bias. Although this is possible, recent publications have identified the lack of
quality data on AMR and large international initiatives (e.g., Fleming Fund, UK) are underway to
bridge the challenges reported here [8,10,11,33,34]. This suggests that problems highlighted in our
small sample set are to a large degree transferable beyond the ’interviewees’ countries and setting.
In addition, the TPP might have been influenced by preconceived notions of what a simplified BC
tool should look like. However, given the separation of minimum and optimal criteria, as well as an
extensive list of 33 characteristics, it is believed that the TPP will be widely applicable and lessons
learned here can be applied to BC systems.
The vision for the TPP is to simplify work for the laboratory needs, while not necessarily being
simple for the innovator. In general, despite the daunting list of requirements, it should be noted
that a system that meets a subset of the characteristics and is designed with the procurement and
capacity challenges of resource-limited settings in mind would be a substantial improvement on
current BC systems.
In conclusion, a simplified BC system would enable expanded use of BCs in low-resource areas.
BC is an essential tool to inform treatment and management of bloodstream infection and the interviews
with different stakeholders highlighted the continued need for phenotypic detection tools beyond
diagnostic tools that can only identify selected pathogens and resistance markers. Tools like these
provide crucial surveillance information that is currently largely unavailable in LIMCs [11]. To ensure
that all these tools are available, a joint effort from academia and industry, as well as global health
organizations, is needed to seed the pipeline of innovations and ensure that infrastructures at all
levels of the health care system are in place to accept improved BC technology. In an ideal scenario,
these improved capacities extend beyond the reference level and cover all levels of the health system to
ensure all severely sick patients in need of appropriate treatment at hospitals can receive a diagnostic
test that will inform the choice of antibiotics for improved outcomes, as well as fostering antibiotic
stewardship and AMR surveillance.
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